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clbj&ws. This stndy songbt to deteradae tbe bag-term risk of 
sudden CaNliac ddl in patients witb he~lly stable 
sustabtcd ventrhdar tackycardii complicatiag ammary artery 
direas% 
Resfk seventy-dght patients wcrc trcatcd pllarmaqly 
(medical glwp), aad 46 patieats Mdenvent map-gaided saben- 
The long-term prognosis and 11k of sudden cardiac death in 
patients with a history of myocardial infarction who develop 
ventricuhr tadtyarrhythmias have not been clearly detined. 
previous studies have reported a l-year Ltcidence of sudden 
mrdiacdeath~~fromaslowas2%toashighas83% 
(l-7). Most of these studies have grouped patients presenting 
with hemodynamicaUy stable ventricular tachycardia together 
with survims of cardiac arrest, and most have included 
patients with a variety of underlying cardiac disorders. Recent 
analyses have suggested that the risk of sudden death is not 
uniform among all patients with ventricular tachyarrhythmias 
but, rather, is dependent on the hemodynamic e&x s of the 
ar@thmii and on the presence and m of underlying heart 
disease (1,4,g,9). Patients who have hemodynamically stable 
docardial rcscctioo (sttrgical group). Ni patients (93%) died 
suddenly, 5 (4.0%) died of ooacardiac caases, 9 (9.3%) died of a 




death (p = 0.049) and total mortality (p = 0.036) were higher ia 
patients with maltivessei disease aad were similar for botk 
treatment groups. 
fLLhe&ons. AlthougJt the overall mortality ia postWrction 
patients presenttmg with -catty stable veatrhtdar 
tad~ycardia trcatcd w&h electrophysiologicaUy gulded antiar- 
rbytbmic therapy is k&k, the risk of sadden death ia these 
patients appears to bc low (averuge 2.4%&u). 
(J Am Gdl conlid 1!@~2&122-9) 
ventricular tachycardia in the absence of structural heart 
disease are at low risk for sudden death (10). Conversely, 
patients who present with hemodynamicalfy stable ventricular 
tachycardia accompanying nonischemic dilated cardiomyopa- 
thy may be at significant risk for sudden death, even when the 
tachycardia appears to be adequately treated (11). The risk of 
sudden death is less clear in patients with hemodynamically 
stable ventricular tachycardia following myotzdial infarction, 
the most frequent cause of sustained monomorphic ventricular 
tachycardia. 
Defining the risk of sudden death in patients with sustained 
ventricular tachycardia following myoeardial infarction is im- 
portant because it may in5uence the choice of therapy. Cfini- 
cians associate ventricular tachyarrhythmias with a high risk of 
sudden death, and often utihze implantable cardioverted 
defibrillatora without regard for the hemodynamic etbxts of 
the patient’s chnical atrhythm& Although it bas been sug- 
gested that implantable cardiirter/defators deaease the 
incidence of sudden cardiac death, most reporta have been 
limited by the use of historical controls, heterogeneous study 
populations that have included patients with hensodynamlcalhl 
stable and unstable anhy&mias, and a variety of mtde&@ 
cardiac diseaw (12-14). Fur&ermore, the risk of sudden 
death in pfttknts with snstahd ventricular tachycardia after 
o73s-1097i%$15.00 
PlJ sims-lo9?((%)oolz 
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myocardial infarction treated with pharmacologic antiarrhyth- 
mic therapy is not clear. 
In order to better detine the long-term prognosis and risk of 
sudden death in a h0mkene.ou.s group of patients, we per- 
formed a retrospective cohort analysis of patients presenting 
with hemodynamically stable ventricular tachycardia after a 
remote myocardial infarction who received electrophysio- 
logically guided treatment a; a time preceding the general 
availability of third-generation implantable cardioverter/ 
delibrillators. 
Methods 
Patient seleetiun. Patients were selected for inclusion 
solely on the basis of their presenting arrhythmia and history of 
myocardial infarction without any knowledge of subsequent 
therapy. In addition, the date of the index infarction and dates 
of all episodes of spontaneous sustained ventricular tachycar- 
dia had to be known for each patient. One-hundred thirty 
patients referred to the Hospital of the University of Pennsyl- 
vania between 1981 azd 1990 with documented hemodynami- 
ally stable monomorphic ventricular tachycardii occurring at 
least 2 weeks after myocardial infarction who met the above 
additional requirements comprised the study population. He- 
modynamkally stable ventricular tachycardia was that which 
did not precipitate cardiac arrest, cause sustained loss of 
consciousness or require emergent termination to preserve 
life. Patients who experienced syncope at the onset of ventric- 
ular tachycardia were included if sG?tained ventricular tachy- 
cardia persisted after recoveq of consciousness. No patient 
had a history of ventricular fibrillation or cardiac arrest remote 
from acute infarction, and none of the episodes of ventricular 
tachycardia were associated with a new infarction. Patients 
whose spontaneous arrhythmia could be attributed to eleetro- 
lyte or metabolic abnormalities or proarrhythmia were ex- 
ChIded. 
&ek9&siolugie study. All patients underwent electro- 
physiologic testing. In 126 patients, all antiarrhythmic medica- 
tions were diintinued at least 5 half-lives before the initial 
electrophysiologic study. It was necessary to continue antiar- 
rhythmic agents in four patients because of frequent or inces- 
sant episodes of ventricular tachyca-dia. 
Programmed stimulation, using a previously described pro- 
tocol (1.5), included the introduction of one, two and three 
ventricular extrastimuli during sinus rhythm and ventricular 
pacing at z-2 cyde lengths, usually 600 and 400 ms, at two right 
ventricular sites. Burst pacing and left ventricular stimulation 
was performed if no arrhythmia could be induced during 
standard right ventricular stimulation. An attempt was made to 
reproduce each patient’s diniil arrhythmia when the rate and 
cmfigmxtion of the spontaneous ventricular taclqrrardia were 
kpwn. The end point of testing was reproducii induct& of 
sustained monomorphic ventricular tachycardia or completion 
of the study protocol. 
Tberapywasasses&atrepeateMrophy&dogicstudy 
before discharge from the hospital in 109 patients (83.8%). and 
utiliid the same stimulation protocol as the baseline study. 
The stimulation protocol was continued through completion of 
three extrastimuli at at least two right ventricular sites, and r2 
paced cycle lengths. The end point for the follow-up electro- 
physiologic study was induction of sustained ventricular tachy 
cardia. Even if ventricular tachycardia was induced by one or 
two extrastimuli at the baseline study, the foilow-up study did 
not end until sustained ventricular tachycardia was induced or 
the stimulation protocol through three extrastimuli at both 
right ventricular stimulation sites, and ~2 paced cycle lengths 
was completed. Repeat electrophysiologic testing was not 
performed in seven patients who died after subendocardial 
resection, five patients who received amiodarone after failii 
several conventional drug trials using electrophysiologic test- 
ing, three patients whose therapy was guided by clinical 
response (suppression of frequent or incessant spontaneous 
ventricular tachycardia), three patients who refused follow-up 
electrophysiologic testing, two patients who had no iuduciiie 
ventricular tachycardia at baseline study and in one patient 
who developed a pulmonary emholus after the baseline study. 
The goal of therapy was noninduciiility at discharge elec- 
trophysiologic study and was prospectively defined as the 
induction of fewer than 16 complexes of ventricular tachy~- 
dia. When this could not be achieved, therapy was aimed at the 
prolongation of induced ventricular tachycardia cycle length to 
optimize hemodynamic stability during the induced ventricular 
tachycardia. 
Treatment. Decisions regarding treatment were made col- 
lectively by the electrophysiology group. Six patients ultimately 
received an implantable defibrillator for persistently iuduciile 
unstable ventricular tachycardia and will he amsidered sepa- 
rately. Of the remaining 124 patients, 78 (63%) were treated 
pharmacologically (medii group), and 46 (37%) underwent 
map-guided subendocardial resection (surgery goup). Criteria 
med to select patients for surgery included th: need for 
myocardiai revascularization, irito!erance to an&rhythmic 
medication,demonstratedinetficacyofpharmac&gictherapy, 
and patient preference. None of the patients in the medical 
group underwent myccardiai revaxularizatioll while 11 pa- 
tienk (24%) in the surgical group underwent concomitant 
coronary bypass graft&. Sixteen patients (34.7%) in the 
surgery group received adjunctive pharmacologic therapy for 
per&ten+ inducii ventricular tachycardia postoperatively. 
‘Ihe pharmacok@c agenk used to treat ail patients are de- 
picted in Fii 1. Our group was not using any investigational 
ant- agenk during the period of this study. 
Outauueevenk. ThePrimatyendpointoftheanalysiiwas 
total mortality. secondary end points included cardiac death, 
sudden cardiac death, and recurrent ventricular tachycardia. 
Sudden cardiacdeath was deiined as-d death occurring 
within 1 h after the onset of symptoms, unwitnessed but 
me@ death, or death tzmhng during sleep SuAned 
ventridar tadycadwas defined aswWiadar tadyanG 
IastingmorethanJosorrequiriugterminationbeGWseof 
hemodynamiccompromiseinlessthan3Os 
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Figure 1. Dismhution of phatmacclogic antiarrhythmic agents admin- 
istered to patients. 1A = type 1A agents (disopyramide, procainamide 
and quinidii); 1B = type 1B agents (mexiletine and tocainide); 1A + 
1B = combination therapy with quinidine or procainamide plus 
mexiletine; 1C = type 1C agents (flecainide and propafenone); Ami- 
o&one comb = amiodanme plus quinidine or procainamide or 
mexiletine; Other = propranolol, verapamil, propafenone plus quini- 
dine and flea&ride plus tocain&. 
FoIIow-up. Patients were followed up for a mean of 36 2 
30 months (range 1 day to 120 months). Follow-up began on 
the date of the first electrophysiologic study and ended on the 
date of the patient’s death or the time of last foltow-up. 
StatIstIcaI analysis. Continuous data are presented as 
mean value -t SD. Basic comparative statistics were calculated 
using the chi-square test and the Student t test. Actuarial 
curves for sudden cardiac death and total mortality were 
constructed using the Kaplan-Meier method and were com- 
pared with the generalized Wilcoxon test. Univariate regres- 
sion analysis using the Cox proportional hazard model with the 
Breslow modification for tied data was applied to all indepen- 
dent variables to determine an association with sudden death 
or total mortality. Multivariate regression analysis was applied 
to all variables that had a predictive value at the level p < 0.10. 
TabIe 1 lists the 21 clinical, electrophysiologic and treatment 
variabIes analyzed. A p value < 0.05 was considered significant 
for all analyses. 
Results 
Cliiical characteristics. A significant majority of the pa- 
tients were male (Table 2). Most patients had multivessel 
coronary artery disease, markedly depressed left ventricular 
ejection fraction and ventricular aneurysm (Table 2). It is 
noteworthy that the median interval between the index infarc- 
tion and the first episode of ventricular tachycardia was over 
3.5 years (Table 2). A majority of the patients had more than 
one episode of ventricuI~ tachycardia and had failed more 
than one trial of empiric antiar&y&mic drug therapy before 
referral (Table 2). There was no sign&ant diierence in any 
chnical variable when patients in the medical group were 
camped with patients in the swgicaI group. 
MorCo&. There were 45 deaths (36.3%) during the 
foIIow-up period. No patient was lost to follow-up; however, 




No. of epicardial veaszls with ~70% stenosis 
LV ejection fraction 
Presence of LV aneurysm 
Prior CABG 
Multiple vs. single infarction 
Interval between index infarction and fiat episode of VT 
No. of spontaneous episodes of VT 
No. of failed empiric antiarrb&nic drug trials 
Empiric use of antiarrhythmic drugs after infarction 
Spontaneous VT cycle length 
Electrophysiologic variables 
Shortest cycle length of VT induced at baseline study 
Shortest cycle length of VT induced at discharge study 
No. of VES required to induce VT at baseline and discharge study 
Hemodyaamic stability of induced VT 
Inducible VT at discharge study 
Change io VT cycle length between baseline and discharge study 
Treatment variables 
Mxlical vs. surgical therapy 
Use of amiodarone 
CABG = coronary artery bypass graft surgery; LV = let ventricul~ VES = 
ventricular extrasdnmIi; VT = ventricular tachycardia. 
the cause of death could not be determined in two patients 
(1.6%). Five patients (4.0%) died of noncardiac causes (two 
from pneumonia, one each of gastritis, stroke and sepsis). Nine 
surgical patients died during the ,perioperative period, resuh- 
ing in an operative mortality of 19.7%. None of these deaths 
was the result of a ventricular arrhythmia. A total of nine 
patients (7.3%) died suddenly, and 20 patients (23.4%) died 
from other cardiac causes (18 from progressive heart failure, 2 
from recurrent infarction). 
Actuarial survival curves for sudden cardiac death and total 
mortality for all patients are shown in Figure 2. At 1,2 and 3 
years, sudden death occurred at cumulative rates of 2 t 1%. 
3 5 2% and 7 + 3 percent of the patients, respectively, and 
death from any cause occurred in 20 ? 4%, 28 2 4% and 32 2 
5% of the patients. Actuarial survival was decreased signiti- 
candy in the surgical group as a result of the relatively high 
operative mortality. However, actuarial curves for sudden 
death and total mortality were similar for both medic&y and 
surgically treated patients who survived the hospital period. 
Antianaythmif therapy. The results of long-term antiar- 
rhythmic therapy are summarized in Table 3. Long-term 
survival was similar for hospital survivors in both treatment 
groups: 26 (70.3%) of the 37 hospital survivors in the surgery 
group and 54 (69.2%) of the 78 hospital survivors in the 
medical group were aliie at the end of the study period. 
Surgery was more efficacious than pharmacologic therapy 
alone at rendering tachycardias noninducibIe at follow-up 
electrophyuiologic testing. At discharge eIec&ophysioIogic test- 
ing, 28 ,(75.7%) of the 37 hospital smvivors inthesnrgay 
group and 20 (29.7%) of the 65 patients in the medical group 
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Table 2. Clinhl Character&i= of Studv Grows 
All Patients Medical Group Surgul Group 
(n = 124) (n = 78) (n = 46) 
Ma W age 62 k Ill 62 2 9 61 + 11 
Male (7) 84.6 71.4 89. I 
LV ejeztii fraction (Q) (n = 79) 31 2 13 342 13 29112 
No. of coronary arteries with ~70% stewsis (a) (a = 9%)’ 
1 48.0 53.3 405 
2 23.5 28.3 18.9 
3 24.5 16.7 35.1 
LMCA 3.1 1.7 5.4 
LV (%) (a = 107) aaeurysm 60.0 555 65.9 
Spontanews VI’ cyde length (ms) (n = 75) 355 5 1s 361’78 344 f 67 
No. of spontaneous VT episodes 1.9 2 1.2 1.9 2 1.1 1.9 2 1.2 
No. of failed empiric drug II& before EPS 1.3 2 1.0 1.3 i 1.0 1.2 e 1.0 
Multiple infaretioos (%) 20.2 23.1 15.2 
Prior CABG (%) 19.4 23.1 13 
Median interval between infarchn aad fint episode VT (months) 45291 53 z 99 29%!94 
*One padem in the medii group had no coronary lesion ~70%. There were no sign&am differem behveen 
medii and swgical group Uala &en+ise spacifwd, data presented are mean values 2 SD. EPS = elearoptgsiologif 
studu; LMCA = left maia coronary artery; other abbreviarioas as in Table 1. 
had no inducible ventricular tachycardia (p < .OOl, surgical vs 
medical group). There was a trend that did not reach statistical 
signiticance for a lower risk of sudden cardiac death in patients 
treated surgically. 
Sudden cardiac death occurred in 2 (4.3%) of the 47 
patients who had no inducible tachycardia at discharge elec- 
trophysiologic study, 5 (9.3%) of 54 patients whose tachyycardia 
remained inducible and 2 (14.3%) of 14 patients who were not 
studied at discharge electropbysiologic evaluation (Table 3). 
Nonsudden cardiac death occurred in 19.1%, 13.2% and 28.6% 
of the patients whose tachycardias were noninducible, induc- 
ible and not studied at discharge, respectively. 
A&yUm& ~~~TCIW Recurrent ventricular tachycardia 
occmred in 11(20.4%) of 54 survivors in the medical group 
and 1 (4.G%) of 25 survivors in the surgery group. Actuarial 
pigpre 2. Actuarial curves for sudden eardiic death (KID) and total 
mortality. Dashed linea = extensions of curves beyond the last event to 
the longest follow-up period, numbers adjacent to the line-s = number 
of patients remaining at risk at yearly intervals. 
freedom from nonfatal recurrent ventricular tachycardia was 
100% and 88% at 36 months in the sqjcal and medical 
groups, respectively @ = 0.0795, Fig. 3). Two (5.7%) of the 35 
sutvivors who had no inducible ventricular tachycardia at 
discharge and 8 (21.1%) of the 38 sutvivors who had induciiie 
ventricular tachycardia at discharge experienced recurrent 
ventricular tachycardia during the follow-up period (p = 
0.077). Two additional patients with hemodynamicaily stable 
tachycardii recurrences were placed on amiodarone but did 
not undergo electrophysiologic study on amiodarone. 
Uuiva&tep&&torsof~TheresultsofcOnre- 
gression analysis for univariate predictors of total mortality are 
shown in Table 4. when examined as a conti~ous variable, 
ejection fraction was a sign&cant predictor of total mortality 
@ = 0.042); however, this signi6cance was lost when the 
ejection fraction was examined as a dichotomous variable with 
the data stratified at a value of 30%. Age more than 62 years, 
multivessel coronary artery disease and a longer cycle length 
(MOO ms) of ventricular tachycardia induced at dis&arge 
study were alI associated with increased mortality. The pres- 
ence of a left ventricuhu aneurysm was associated with a better 
progno&. single-vessel coronaty dii was present in 57.8% 
of the patients with a left ventricular aneurysm compared to 
only 35.1% of the patients without an aneurysm (p = 0.03). 
Multivariate analysis identified only multivessel COiSCary ar- 
tery disease as an independent predictor of total mortality. Cox 
regression arm&is failed to identify any significant predictors 
for sudden cardiac death, presumably because of the small 
number of sudden death events. 
Ammid smvival adysis reveakd ‘that the extent of 
coronary artery dise;tse correlated withboth alI cause mortality 
@ = 0.036) and sudden cardiac death (p = 0.047). Figure 4A 
displays the actuarial smvival anves for total mortality in 
patients with single and multiveasel coronary artery disease. 
126 SARTER ET AL. 
DEATH RISK OF SUSTAINED VENTRICULAR TACHYCARDIA 
Table 3. Outcome of Long-Term Antiarrhythmic Therapy in Hospital Survivors 
JACC Vol. ZR, No. 1 
July 1996:122-9 
No. of No. of No. of Cardiac Deaths No. of Total 
Patients Sudden Deaths (CHF or MI) Deaths* 
Mediil therapy 
Noninducible at discharge EPS 19 I 3 5 
IndunMe at discharge EPS 45 4 5 11 
Discharge EPS not performed 14 2 4 8 
Total 78 
Surgical therapy 
Noninducible at discharge EPS 28 I 6 8 
Indu&ie at discharge EPS 9 1 7 4 
Discharge EPS not performed 0 0 0 0 
Total 37 
Totals? 115 9 (7.8) 20 (! 1.4) 36 (31.3) 
*Includes noncardiac deaths. tNomben in parentheses arc percent of total group; nine patients who died 
perioperatively are excluded. EPS = electqbysiologic stody. 
The I-, 2- and 3-year survival in patients with single-vessel 
coronary artery disease was 85 t 5%, 82 + 6% and 79 5 6%, 
respectively. Survival in patients with multivessel coronary 
artery was significantly lower, with 80 C 6%, 66 2 7% and 58 t 
8% survival over the same yearly periods. 
Figure 4B displays the actuarial survival curves for sudden 
cardiac death. At 3 years of follow-up, no patient with single- 
vessel coronary disease died suddenly, but 14 t 7% of patients 
with multivessel coronary artery disease had died from sudden 
cardiac death. 
Discbarge ventricular tacbycardii cycle length and tber- 
apy. The negative relation between the cycle length of ven- 
tricular tachycardia induced at the discharge electrophysiologic 
study and survival surprised us. To determine whether this 
observation was related to the use of pharmacologic antiar- 
rhythmic therapy, we compared the cycle length of ventricular 
tachycardia induced at the discharge electrophysiologic study 
with the difference between the cycle lengths of ventricular 
tachycardia induced at the baseline and the discharge electro- 
physiologic studies (Fig. 5). In each case, the shortest mono- 
morphic ventricular tachycardia cycle length induced at each 
study was compared, without regard for tachycardia configu- 
F&ire 3. Actuarial curves for nonfatal recurrent ventricular tachycar- 
dia stratified by treatment modality. Format as in Figure 2. 
Ol 0 24’ 48 72 96 
Foltow-up (mootho) 
ratid,:. The cycle length of ventricular tachycardia induced at 
discharge was correlated significantly with the change in cycle 
length induced in the presence of therapy (R’ = 0.67, p < 
0.0001). The increase in ventricular tachycardia cycle length 
was attributable to antianhythmic drugs in each case and did 
not result from an effect of subendocardial resection. The 
changes in ventricular tachycardia cycle length did not appear 
to be related to a specific antiarrhythmic agent. The few cases 
in which a shorter cycle length of ventricular tachycardia was 
induced at the discharge study than at the baseline study did 
not result from a decrease in cycle length of the same 
configuration of tachycardia. 
Patients with implantable cardioverter/deQbriQaturs. The 
six patients who received an impiantable cardioverter/ 
defibrillator were followed up for a mean of 23 i: 8 months. In 
comparison with the other 124 patients, the patients who 
received implantable defibrillators were more likely to have 
multivessel coronary artery disease (p = 0.034) and prior 
coronary artery bypass grafting (p = 0.0002). Two of the six 
patients (33.3%) experienced an implantable cardioverterl 
defibrillator discharge over the follow-up period, and all six 
patients were alive at the end of the follow-up period. 
Discussion 
The purpose of this study was to determine the long-term 
prognosis and risk of sudden cardiac death in a select group of 
Table 4 Univariate Predictors of Ail-Cause Mortalily 
Variable 
Age >62 yr 
Multive& CAD’ 
Presence of LV aneurysm 
Cycle length of VT induced at 
discharge EPS >’ 400 ms 
RR (95% CI) p value -- 
1.96 (1.02-358) 0.+4 
2.u8 (1.03-4.22) 0.042 
0.53 (0.2&1.00) 0.049 
3.38 (1.13-10.07) 0.029 
*Multivessel coronary artery dii (CAD) was the only multiie 
predictor of all-cause mortality (relatiw risk [RR] 1.80,9% confidence interval 
[Cl] LO&3.00. p = 0.024). Other abbreviations &E in Tables 1 and 2 
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Flgwo 4. Actuarial curves for total mortality (A) and sudden cardiac 
death (8) stratifled by extent of coronary artery disease. Light lines = 
patients with single-vessel disease; heavy lines = patients with mul- 
tivessel disease; other symbols as in Figure 2. 
patients with prior infarction who presented with hemodynam- 
icaUy stable monomorphic ventricular tachycardii Our find- 
ings emphasize the importance of the ctinical history in deter- 
mining the most appropriate antiarrhythmic therapy in 
patients who develop ventricular tachyarrhythmias after infarc- 
tion. We were able to identify a group of patients at low risk for 
sudden death atier receiving electrophysiologically guided 
antiarrhythmic therapy based on their history of infarction and 
stable presenting arrhythmia. 
coarparlson with prior studies. Previous studies investigat- 
ing the prognosis of patients who present with ventricular 
tachyarrhythmias have demonstrated a variable risk of sudden 
death (l-7). A high incidence of sudden death has been 
reported in studies that have included survivors of cardiac 
arrest and patients with nonischemic cardiac disease (3-6). 
The few studies that analyted patients with iscbemic heart 
disease and hemodynamicaIIy tolerated tachycardias sepa- 
rately demonstrated a lower sudden death Fate (1,2,7). 
BN@ et al. (1) demonstrated a 2.1% incidence of sudden 
death over a mean follow-up period of 26 months in 140 
postinfarction patients presenting with hemodynamically sta- 
ble ventricular tachycardia or symptomatic nonsustained ven- 
tricular tachycardia. DiMarco et al. (2) reported that sudden 
death occurred in only 5% of 40 patients over a mean 
follow-up period of 15 months who developed sustained ven- 
tricnhu tachycardia within 2 months of infarction. Our results 
are simihx to these Gmiings but extend the longest reported 
foIIow-up period by 1 year. Oniy 9 (7.?%) of the 124 patients 
ia our study died suddenly over the mean folhwup period of 
3 years (average 2.4% per, year). Total mortality was sign& 
car&y higher in our patients; 36.3% died during the follow-up 
period. Nonsudden cardiac death from perioperative death, 
progressive heart faihuz or FeenFNnt inf3Fctiotl Ilcmmed foF 
64% of the. deaths. Nonsudden cardiac death occurred more 
Fttre 5. Correlation of cycle length (CL) of sustained monomorphic 
ventricular tachycardia (VT) induced at the discharge electmphysi- 
ologic study and change in induced ventricular tachycardia cycle length 
from baseline to discharge electrophysiologic study. x axis = cycle 
length of ventricular tachwia induced at the discharge electqhy& 
ologic stu& y ads = diierence in cycle length between sustained 
ventricular tachycardia induced at baseline versus discharge electro- 
physiologic study. In each case, the shortest cycle length of tachycardia 
induced is compared, without regard for tachycardia conliguration. 
R’ = 0.67, p < 0.0001. 
frequently than sdden death in both the medically and 
surgicaIIy treated patients. 
In a series of 50 patients with stable ventricular tachycardii 
complicating a variety of muledying heart diseases, Etocker et 
al. (16) recently estimated an incidence of life-threatening 
ventricular tachycardias of 22% after a mean follow-up of only 
17 months. It is diEcult to compare this series directly with 
ours because the patients had a variety of underlying heart 
disease (although coronary disease was predominant), endo- 
cardial resection was not utilized, and the end points used for 
amdysis were events retrieved from implanted cardioverted 
defibriIIators. In addition, patients were not entered in this 
series unkss they had failed serial drug testing (mean 3.1 
trials). Backer et al. (16) observed no nonarrhythmic deaths, 
which may relate in part to the short duration of follow-up and 
lack of surgical therapy. The incidence of sudden death was 2% 
in this series, similar to that whiih we observed without the use 
of defibrillators. 
Factors assn&ed x&b mnrt&ty. The overall incidence of 
sudden cardiac death in hospital smvivors in our wgicai group 
was 5.4% compared with 9.1% in the medical group. ‘Ihis trqnd 
toward a lower incidence of sudden death may have been 
related to the higher in-hospital mortality in the surgery group, 
which might have selected out the patients more likely to die 
suddenly. We think this is an unlikely explanation and believe 
that thii ?-end suggests that improvements in surgicai tech- 
niques OF the use of other fOnnS of ablative therapy (e.g., 
radiofrequency catheter ablation) may result in improved 
sutviv3l. 
The association between increasing ,age and muItivesse1 
coromry artery disease with higher mortality in our patients is 
in agreement with the findings of other investigators (4,6,9). 
The rippent protective effect of a left ventricular aneurysm 
on smvivaI in our patients may have been related to the. higher 
prevalence of single-vessel OoFOnaFy artery disease in these 
p3tients. 
surprisingty, we found that a longer venhicular tachycardia 
eyde Iettgth (slower rate) at discharge electmphysio&c study 
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was associated with a poorer outcbme. This may at first seem 
counterintuitive and contradictory to the findings of other 
investigators. Wailer and colleagues (17) demonstrated im- 
proved survival when hntiarrhythmic therapy resulted in a 
reduction of symptoms and a more than MO-ms prolongation 
in cycle length during induced ventricular tachycardia. A direct 
comparison of our results with Walter’s is limited in that these 
authors included patients with a mixture of cardiac diseases 
and arrhythmia presentatio.;* qvhereas our study subjects 
included only postinfarction patients with stable ventricular 
tachycardia. Interestingly, the subgroup of patients in Walier’s 
study whose therapy resulted in a ventricular tachycardia cycle 
length >4OCl ms appeared to have a higher r$ortaMy, a finding 
consistent with our results. 
To investigate further the mechanism for the association 
between ventricular tachycardia cycle length at discharge and 
mortality, we postulated that the poorer outcome in patients 
with longer ventricular tachycardia cycle length could be 
related to a greater (and possibly adverse) pharmacologic 
effect in these patients. The significant correlation between the 
change in ventricular tachycardia cycle length after therapy 
and induced ventricular tachycardia cycle length at discharge 
(Fig. 5) suggests that longer ventricular tachycardia cycle 
length at discharge was indeed due to drug effect. This further 
suggests that the aggressive titration of antiarrhytbmit: aeents 
in order to produce maximal slowing of ventricular tachycardia 
cycle length may have had an adverse effect in some of our 
patients. 
These observations should make it apparent that the choice 
of antiarrhythmic therapy for patients with hemodynamically 
stable sustained ventricular tachycardia following myocardial 
infarction is an extremely complex matter, not easily given over 
to algorithms. Therapy must be individualized in each case, 
and multiple factors must be taken into consideration. These 
factors include not only those directly related to the arrhythmia 
but also those relating to the extent of coronary artery disease 
and the potential for recurrent ischemia. 
Study liitations. Our analysis is retrospective and treat- 
ment was not assigned randomly. In addition, our results may 
be affected by selection bias, similar to that which affects any 
series of patients reported by tertiary referral institutions. 
The separate analysii of the six patients who received an 
implantable defibrillator may have eliminated those patients at 
highest risk for sudden death. Importantly, only two of the six 
patients experienced an implantable cardioverter/defibrillator 
discharge ovq 23 months of follow-up. Unfortunately, the 
device that these patients received does not store electrograms 
or tachycardii cycle lengths, so it is diicult to determine the 
specific arrhythmias that led to device-delivered therapy. It is 
quite possible that the aborted arrhythmia may have been well 
tolerated. Even if these twu events are counted as episodes of 
sudden death, the incidence of sudden death would remain 
low-8.5% for all patients. 
Finally, the impact of newer therapy such as converting 
enzyme inhibitors, which have been shown to reduce mortality 
in postinfarction patients, could not be evaluated because the 
study period predated the common use of these agents in the 
postinfarction setting (18,19). This may be especially important 
in view of the high incidence of death from heart failure in our 
patients. 
Conclusions. Although overall mortality in postinfarction 
patients presenting with hemodynamically stable ventricular 
tachycardia treated with electrophysiologically guided antiar- 
rhythmic therapy is high, the risk of sudden cardiac death 
appears to ‘rp low. Because of the low risk of sudden death in 
these patients, aggressive antiarrhythmic therapy with implant- 
able defibrillators or high do:-e pharmacologic therapy may not 
improve survival dramatically. Our finding of increased mor- 
tality associated with longer cycle lengths of ventricular tachy- 
cardia induced after pharmacologic therapy raises the possi- 
bility of proarrhythmic drug effects in these patients. 
We wish to a& .wledge the valuable support of the technicians and nurses of 
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